X4 Pharmaceuticals (XFOR) Debt Ratio (2017 - 2026)

X4 Pharmaceuticals (XFOR) has reported Debt Ratio for 10 consecutive years, with 0.3 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Debt Ratio fell 57.94% year-over-year to 0.3; the trailing twelve-month figure through Jun 2026 stood at 0.3 (down 57.94% YoY), and the FY2025 full-year result was 0.26, down 49.0% from the prior year.
• Debt Ratio rose to 0.3 in Q2 2026 per XFOR's latest filing, from 0.28 in the prior quarter.
• Across five years, Debt Ratio topped out at 0.72 in Q2 2025 and bottomed at 0.19 in Q2 2023.
• Historically, Debt Ratio has averaged 0.39 across 5 years, with a median of 0.37 in 2022.
• The sharpest annual moves came in 2022 and 2023: Debt Ratio surged 114.28% in 2022, then slumped 62.19% in 2023.
• Over 5 years, Debt Ratio stood at 0.22 in 2022, then jumped by 71.85% to 0.37 in 2023, then jumped by 37.9% to 0.52 in 2024, then tumbled by 49.0% to 0.26 in 2025, then grew by 15.48% to 0.3 in 2026.
• According to Business Quant data, Debt Ratio over the past three periods registered 0.3, 0.28, and 0.26 for Q2 2026, Q1 2026, and Q4 2025 respectively.